A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

Name: A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
Published: 2026
License: Public Domain

Dai, Guanghai · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

advanced ras-mutated colorectal cancer with liver metastases (crlm), interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

Related documents